NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors

BMC Cancer

Volumn 12, Issue , 2012, Pages

  McCarthy, Brian A ^a   Yang, Liqun ^a,b   Ding, Jane ^a   Ren, Mingqiang ^a   King, William ^a   ElSalanty, Mohammed ^a   Zakhary, Ibrahim ^a   Sharawy, Mohamed ^a   Cui, Hongjuan ^b   Ding, Han Fei ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b SOUTHWEST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CYCLIN D1; CYCLIN D2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN 2; INTERLEUKIN 10; INTERLEUKIN 15; M PROTEIN; STAT3 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BLIMP1 GENE; BONE LESION; BONE MARROW; CANCER CELL CULTURE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1 GENE; CYCLIN D2 GENE; DISEASE MODEL; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IL10 GENE; IL15 GENE; IN VITRO STUDY; LYMPHOCYTE; LYMPHOMA; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; MOUSE; MULTIPLE MYELOMA; NF KB2 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOLYSIS; OSTEOPOROSIS; PLASMA CELL; PLASMACYTOMA; SIGNAL TRANSDUCTION; SURVIVIN GENE; TRANSGENIC MOUSE; UNINDEXED SEQUENCE;

ANIMALS; BLOOD PROTEINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; NF-KAPPA B P52 SUBUNIT; PLASMACYTOMA; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861468201     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-203     Document Type: Article

References (50)

1. Beinke S, Ley SC. Functions of NF-κB1 and NF-κB2 in immune cell biology. Biochem J 2004, 382(Pt 2):393-409. 1133795, 15214841.
2. Gilmore TD. Introduction to NF-κB: players, pathways, perspectives. Oncogene 2006, 25(51):6680-6684. 10.1038/sj.onc.1209954, 17072321.
3. Basseres DS, Baldwin AS. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25(51):6817-6830. 10.1038/sj.onc.1209942, 17072330.
4. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5(10):749-759. 10.1038/nri1703, 16175180.
5. Courtois G, Gilmore TD. Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene 2006, 25(51):6831-6843. 10.1038/sj.onc.1209939, 17072331.
6. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12(2):115-130. 10.1016/j.ccr.2007.07.004, 2730509, 17692804.
7. Derudder E, Laferte A, Ferreira V, Mishal Z, Baud V, Tarantino N, Korner M. Identification and characterization of p100HB, a new mutant form of p100/NF-κB2. Biochem Biophys Res Commun 2003, 308(4):744-749. 10.1016/S0006-291X(03)01474-8, 12927781.
8. Fracchiolla NS, Lombardi L, Salina M, Migliazza A, Baldini L, Berti E, Cro L, Polli E, Maiolo AT, Neri A. Structural alterations of the NF-κB transcription factor lyt-10 in lymphoid malignancies. Oncogene 1993, 8(10):2839-2845.
9. Migliazza A, Lombardi L, Rocchi M, Trecca D, Chang C-C, Antonacci R, Stefano N, Ciana P, Maiolo AT, Neri A. Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. Blood 1994, 84:3850-3860.
10. Neri A, Chang C-C, Lombardi L, Salina M, Corradini P, Maiolo AT, Chaganti RSK, Dalla-Favera R. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50. Cell 1991, 67:1075-1087. 10.1016/0092-8674(91)90285-7, 1760839.
11. Thakur S, Lin HC, Tseng WT, Kumar S, Bravo R, Foss F, Gelinas C, Rabson AB. Rearrangement and altered expression of the NFKB-2 gene in human cutaneous T-lymphoma cells. Oncogene 1994, 9:2335-2344.
12. Zhang J, Chang CC, Lombardi L, Dalla-Favera R. Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions. Oncogene 1994, 9:1931-1937.
13. Zhang B, Wang Z, Li T, Tsitsikov EN, Ding HF. NF-κB2 mutation targets TRAF1 to induce lymphomagenesis. Blood 2007, 110(2):743-751. 10.1182/blood-2006-11-058446, 1924489, 17405906.
14. Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, Chauhan D, Podar K, Mitsiades C, Dang L, et al. MLN120B, a novel IκB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 2006, 12(19):5887-5894. 10.1158/1078-0432.CCR-05-2501, 17020997.
15. Jourdan M, Moreaux J, Vos JD, Hose D, Mahtouk K, Abouladze M, Robert N, Baudard M, Reme T, Romanelli A, et al. Targeting NF-κB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Br J Haematol 2007, 138(2):160-168. 10.1111/j.1365-2141.2007.06629.x, 2494583, 17542984.
16. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and/or alternative NF-κB pathway activation in multiple myeloma. Blood 2010, 115(17):3541-3552. 10.1182/blood-2009-09-243535, 2867265, 20053756.
17. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 2007, 12(2):131-144. 10.1016/j.ccr.2007.07.003, 2083698, 17692805.
18. Pircher H, Mak TW, Lang R, Ballhausen W, Ruedi E, Hengartner H, Zinkernagel RM, Burki K. T cell tolerance to Mlsa encoded antigens in T cell receptor V beta 8.1 chain transgenic mice. EMBO J 1989, 8(3):719-727. 400867, 2524380.
19. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003, 4(5):P3. 10.1186/gb-2003-4-5-p3, 12734009.
20. The International Myeloma Working G Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003, 121(5):749-757. The International Myeloma Working G.
21. Otsuki T, Yata K, Sakaguchi H, Uno M, Fujii T, Wada H, Sugihara T, Ueki A. IL-10 in myeloma cells. Leuk Lymphoma 2002, 43(5):969-974.
22. Agematsu K, Nagumo H, Oguchi Y, Nakazawa T, Fukushima K, Yasui K, Ito S, Kobata T, Morimoto C, Komiyama A. Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction. Blood 1998, 91(1):173-180.
23. Hjorth-Hansen H, Waage A, Borset M. Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells. Br J Haematol 1999, 106(1):28-34. 10.1046/j.1365-2141.1999.01510.x, 10444159.
24. Bahlis NJ, King AM, Kolonias D, Carlson LM, Liu HY, Hussein MA, Terebelo HR, Byrne GE, Levine BL, Boise LH, et al. CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood 2007, 109(11):5002-5010. 10.1182/blood-2006-03-012542, 1885531, 17311991.
25. Robillard N, Jego G, Pellat-Deceunynck C, Pineau D, Puthier D, Mellerin MP, Barille S, Rapp MJ, Harousseau JL, Amiot M, et al. CD28, a marker associated with tumoral expansion in multiple myeloma. Clin Cancer Res 1998, 4(6):1521-1526.
26. Nutt SL, Fairfax KA, Kallies A. BLIMP1 guides the fate of effector B and T cells. Nat Rev Immunol 2007, 7(12):923-927. 10.1038/nri2204, 17965637.
27. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005, 106(1):296-303. 10.1182/blood-2005-01-0034, 1895118, 15755896.
28. Gattei V, Degan M, Gloghini A, De Iuliis A, Improta S, Rossi FM, Aldinucci D, Perin V, Serraino D, Babare R, et al. CD30 Ligand Is Frequently Expressed in Human Hematopoietic Malignancies of Myeloid and Lymphoid Origin. Blood 1997, 89(6):2048-2059.
29. Romagnoli M, Trichet V, David C, Clement M, Moreau P, Bataille R, Barille-Nion S. Significant impact of survivin on myeloma cell growth. Leukemia 2007, 21(5):1070-1078.
30. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765. 10.1146/annurev.immunol.19.1.683, 11244051.
31. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004, 22:929-979. 10.1146/annurev.immunol.22.012703.104622, 15032600.
32. Alvarez JV, Frank DA. Genome-wide analysis of STAT target genes: Elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol Ther 2004, 3(11):1045-1050. 10.4161/cbt.3.11.1172, 15539936.
33. Diehl SA, Schmidlin H, Nagasawa M, van Haren SD, Kwakkenbos MJ, Yasuda E, Beaumont T, Scheeren FA, Spits H. STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation. J Immunol 2008, 180(7):4805-4815. 2396731, 18354204.
34. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip MLR, Jove R, McLaughlin MM, Lawrence NJ, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci 2007, 104(18):7391-7396. 10.1073/pnas.0609757104, 1863497, 17463090.
35. Kuehl WM. Modeling Multiple Myeloma by AID-Dependent Conditional Activation of MYC. Cancer Cell 2008, 13(2):85-87. 10.1016/j.ccr.2008.01.022, 18242508.
36. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, Valdez R, Palmer SE, Haas SS, Stewart AK, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008, 13(2):167-180. 10.1016/j.ccr.2008.01.007, 2255064, 18242516.
37. Avet-Loiseau H, Gerson F, Magrangeas F. Minvielle Sp, Harousseau J-L, Bataille Rg: Rearrangements of the c-myc oncogene are present in 15 % of primary human multiple myeloma tumors. Blood 2001, 98(10):3082-3086. 10.1182/blood.V98.10.3082, 11698294.
38. Speiser DE, Lee SY, Wong B, Arron J, Santana A, Kong YY, Ohashi PS, Choi Y. A regulatory role for TRAF1 in antigen-induced apoptosis of T cells. J Exp Med 1997, 185(10):1777-1783. 10.1084/jem.185.10.1777, 2196328, 9151703.
39. Tinhofer I, Marschitz I, Henn T, Egle A, Greil R. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 2000, 95(2):610-618.
40. Banchereau J, Briere F, Liu YJ, Rousset F. Molecular control of B lymphocyte growth and differentiation. Stem Cells 1994, 12(3):278-288. 10.1002/stem.5530120304, 7521239.
41. Calame KL, Lin KI, Tunyaplin C. Regulatory mechanisms that determine the development and function of plasma cells. Annu Rev Immunol 2003, 21:205-230. 10.1146/annurev.immunol.21.120601.141138, 12524387.
42. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 1992, 89(5):1890-1893. 10.1073/pnas.89.5.1890, 48559, 1371884.
43. Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol 2001, 2(12):1103-1108. 10.1038/ni1201-1103, 11725300.
44. D'Costa K, Emslie D, Metcalf D, Smyth GK, Karnowski A, Kallies A, Nutt SL, Corcoran LM. Blimp1 is limiting for transformation in a mouse plasmacytoma model. Blood 2009, 113(23):5911-5919. 10.1182/blood-2008-08-172866, 19329782.
45. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22(53):8581-8589. 10.1038/sj.onc.1207113, 14634620.
46. Kawakami H, Tomita M, Matsuda T, Ohta T, Tanaka Y, Fujii M, Hatano M, Tokuhisa T, Mori N. Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int J Cancer 2005, 115(6):967-974. 10.1002/ijc.20954, 15729715.
47. Massague J. G1 cell-cycle control and cancer. Nature 2004, 432(7015):298-306. 10.1038/nature03094, 15549091.
48. Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004, 5(2):191-199. 10.1016/S1535-6108(04)00019-4, 14998494.
49. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999, 19(8):5785-5799. 84428, 10409765.
50. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 1999, 19(4):2690-2698. 84062, 10082535.